Recent News
Oct 12, 2021
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

South San Francisco, CA, October 12, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...

Sep 28, 2021
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

South San Francisco, CA, September 28, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...

Stock Info
NASDAQSTSA